Analyst Price Targets — ADMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 14, 2024 6:58 am | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $17.15 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA) |
| June 20, 2024 6:47 am | Anthony Petrone | Mizuho Securities | $14.00 | $10.62 | StreetInsider | ADMA Biologics (ADMA) PT Raised to $14 at Mizuho |
| January 3, 2023 6:14 am | — | H.C. Wainwright | $4.50 | $3.88 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Raises Price Target to $4.5 |
| November 10, 2022 10:24 am | — | Mizuho Securities | $6.00 | $3.05 | Benzinga | Mizuho Maintains Buy on ADMA Biologics, Raises Price Target to $6 |
| July 25, 2022 6:44 am | — | H.C. Wainwright | $4.00 | $2.17 | Benzinga | HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $4 |
Latest News for ADMA
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
ADMA posts 18% Q4 revenue growth as Asceniv drives record 2025 sales, with 2026 revenues seen topping $635M and margins set to expand.
ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADMA.
U.S. House Trading
No House trades found for ADMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.